These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3862584)

  • 1. Aclarubicin (aclacinomycin A) in the treatment of relapsing acute leukaemias.
    Mitrou PS; Kuse R; Anger H; Herrmann R; Bonfert B; Pralle H; Thiel E; Westerhausen M; Mainzer K; Bartels H
    Eur J Cancer Clin Oncol; 1985 Aug; 21(8):919-23. PubMed ID: 3862584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
    Warrell RP; Arlin ZA; Kempin SJ; Young CW
    Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
    Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L
    Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic results with aclacinomycin A in recurring acute leukemias].
    Mitrou PS
    Onkologie; 1983 Aug; 6(4):192-4. PubMed ID: 6355949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia.
    Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Dorval T; Ribaud P
    Biomed Pharmacother; 1984; 38(7):328-31. PubMed ID: 6596962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic trials of aclarubicin in previously treated acute leukemias and hematosarcomas].
    Machover D; Goldschmidt E; Benavides M; Gastiaburu J; Vandenbulcke JM; Delgado M; Misset JL; Mathe G
    Pathol Biol (Paris); 1987 Jan; 35(1):79-86. PubMed ID: 3550616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
    Dabich L; Bull FE; Beltran G; Athens JW; Coltman CA; Weick JK; Van Slyck EJ; Amare M
    Cancer Treat Rep; 1986 Aug; 70(8):967-9. PubMed ID: 3460700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aclacinomycin A: clinical development of a novel anthracycline antibiotic in the haematological cancers.
    Warrell RP
    Drugs Exp Clin Res; 1986; 12(1-3):275-82. PubMed ID: 3525076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aclacinomycin-A in acute leukaemias and leukaemic non-Hodgkin lymphomas (author's transl)].
    Mathé G; de Jager R; Hulhoven R; Delgado M; Machover D; Ribaud P; de Vassal F; Gil-Delgado M; Misset JL; Gouveia J; Jasmin C; Hayat M; Gastiaburu J; Schwarzenberg L
    Nouv Presse Med; 1982 Jan; 11(1):25-8. PubMed ID: 6949137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia.
    Rowe JM; Chang AY; Bennett JM
    Blood; 1988 Apr; 71(4):992-6. PubMed ID: 3162695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of aclarubicin in acute myeloblastic leukemia.
    Case DC; Ervin TJ; Boyd MA; Bove LG; Sonneborn HL; Paul SD
    Am J Clin Oncol; 1987 Dec; 10(6):523-6. PubMed ID: 3479891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of refractory acute leukemia with aclacinomycin-A.
    Takahashi I; Hara M; Adachi T; Takaoka K; Sakano M; Lai M; Kohi F; Yorimitsu S; Tokioka M; Kitajima K; Kimura I; Sanada H
    Acta Med Okayama; 1980 Nov; 34(5):349-54. PubMed ID: 6449134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aclarubicin in single agent and combined chemotherapy of acute myeloid leukaemias.
    Mitrou PS
    Eur J Haematol Suppl; 1987; 47():59-66. PubMed ID: 3471526
    [No Abstract]   [Full Text] [Related]  

  • 14. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
    Pedersen-Bjergaard J; Brincker H; Ellegaard J; Drivsholm A; Freund L; Jensen KB; Jensen MK; Nissen NI
    Cancer Treat Rep; 1984 Oct; 68(10):1233-8. PubMed ID: 6597002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aclarubicin in the treatment of elderly patients with acute nonlymphocytic leukemia.
    Takahashi I; Yorimitsu S; Hara M; Inagaki T; Nakada H; Sekito N; Hayashi N; Nonaka K; Ohmoto E; Uchida K
    Acta Med Okayama; 1986 Jun; 40(3):175-7. PubMed ID: 3461685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aclarubicin in the treatment of relapsed or resistant acute myelogenous leukaemia: a phase II trial.
    Evensen SA; Wisløff F; Müller E; Talstad I; Waage A; Johansen L
    Eur J Haematol Suppl; 1987; 47():43-7. PubMed ID: 3471524
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I-II study of aclarubicin for treatment of acute myeloid leukaemia.
    Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Benavides M; Lotz JP; Misset JL; de Vassal F; Tapiero H
    Eur J Haematol Suppl; 1987; 47():33-42. PubMed ID: 3471523
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical review of aclacinomycin A in Japan.
    Ota K
    Drugs Exp Clin Res; 1985; 11(1):17-21. PubMed ID: 3869800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of aclacinomycin A in acute leukemia and various solid tumors.
    Schütte J; Niederle N; Seeber S
    J Cancer Res Clin Oncol; 1983; 105(2):162-5. PubMed ID: 6572190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical studies of aclacinomycin A (ACM).
    Majima H; Ohta K
    Biomed Pharmacother; 1987; 41(5):233-7. PubMed ID: 3311189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.